ALVIO — Valerio Therapeutics SA Share News
0.000.00%
Last trade - 00:00- €195.03m
- €201.58m
- €2.57m
Brief: Onxeo Announces Transfer Of Listing Of Shares To Euronext Growth Paris
Brief: Onxeo Announces Approval For Delisting From Nasdaq Main Market Copenhagen
Brief: Onxeo Applies For Admission To Trading On Nasdaq First North Growth Market Denmark
Brief: Onxeo Announces Completion Of Enrollment In DRIIV-1b Study And Favorable Interim Results
Brief: Onxeo Receives Notice Of Intent To Grant New Patent
Brief: Onxeo Announces Enrollment Of First Patient In Phase Ib/II Study Revocan
Brief: Onxeo H1 Net Profit At 5 Million Euros
Brief: Onxeo Receives Notice Of Allowance For New Patent in U.S.
Brief: Onxeo: Final Results Of DRIIV Phase 1 Dose-Escalation Study Of Asidna
Brief: Onxeo Reports DRIIV Phase 1 Study Of AsiDNA In Advanced Solid Tumors
Brief: Onxeo: Transfer Of Securities To Euronext Growth
Brief: Onxeo Confirms Preclinical Profile Of OX401
Brief: Onxeo Announces Capital Increase Of 7.3 Million Euros
Brief: Onxeo Announces Approval Of Its REVocan Study
Brief: Onxeo FY Net Loss Widens To 33.8 Million Euros
Brief: Onxeo Enters Into Agreements With Acrotech Biopharma LLC
Brief: Onxeo To Present Next-Generation PARP Inhibitor At European ESMO-TAT Congress 2020
Brief: Onxeo Concludes Settlement Agreement With SpePharm And SpeBio
Brief: Onxeo Partners With Gustave Roussy In Clinical Trial Of AsiDNA Cancer Treatment